본문 바로가기 주메뉴 바로가기
  • HOME
  • Public Relations
  • GC Cell News

GC Cell News

GC Cell Accelerates the Expansion of CDMO Business!
2021-05-14
GC Cell Accelerates the Expansion of CDMO Business!
GC Cell, a company specializing in cell therapy, expanded and reorganized our CDMO business division to reinforce the commissioned development and production business.
With this reorganization, we are focusing on expanding the CDMO business to secure next-generation growth driven by a new organizational structure following approval of production facilities and license.
GC Cell has the largest production facility for cell therapeutics in Korea. We plan to focus and expand the CDMO business for cell and gene therapeutics by using its experience in carrying out many projects such as Cellid, GC LabCell, and Artiva Biotherapeutics Inc.
According to data released by the Biotech Policy Research Center, the global CDMO market for cell& gene therapy is expected to grow sharply at an annual average of 31%, from $1.52 billion in 2019 to $1.101 billion in 2026.
In particular, it is predicted that the market has a very high potential for growth since cell & gene therapeutics are produced through outsourcing (CDMO, etc.) 30-75% in the clinical trial stage and 35-60% in the commercialization stage.
GC Cell has been providing customized solutions for successful IND approval through GMP operational know-how accumulated from 2007 to the present and numerous CDMO project experiences inside and outside of Korea.
This reorganization aims to maximize the expertise and efficiency of business operation by focusing on these capabilities and we plan to provide more systematic project management, quality review, and regulatory support.
GC Cell will become a touchstone in the global CDMO field for cell and gene therapeutics based on our differentiated know-how and reliable competencies.
Next
GC Cell Completes pct for entry into the global market
Previous
GC Cell is pushing ahead with the development of off-the-shelf CAR-CIK cell therapeutics